Beta
ManageSearchChatDiscover
357449

Clinical and immunological response to sublingual allergen-specific immunotherapy: cumulative dose-response relationship

Article

Last updated: 28 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

Clinical microbiology

Abstract

Background: Initial studies on sublingual allergen-specific immunotherapy (SLIT) used low doses, but it soon became clear that cumulative dosages higher than the doses used in subcutaneous immunotherapy (SCIT) were required to guarantee clinical efficacy. Objective: This study aimed to evaluate the cumulative dose-dependent clinical and immunological responses to SLIT. Methodology: Patients with allergic airway diseases were included in the study. Patients underwent a skin prick test (SPT) and then received sublingual allergen-specific immunotherapy. Clinical and immunological response variables were recorded at 0, 3, and 6 months intervals of the SLIT schedule (with progressively increasing doses). Results: The study included 74 patients with allergic airway diseases. Symptom and medication scores significantly decreased from baseline (P <0.0001). Hay-specific IgE levels did not decrease significantly, but mite-specific IgE levels decreased by 146%. Hay-specific IgG4 levels increased by 44. 44% after six months of immunotherapy (P<0.01). Eosinophil cationic protein (ECP) levels decreased significantly in patients who underwent six months of sublingual-swallow immunotherapy. Conclusion: There is a clinical cumulative dose-response relationship after SLIT. However, apart from ECP, the immunological cumulative dose-response relationship varies between the allergens.

DOI

10.21608/ejmm.2024.290825.1250

Keywords

Sublingual-swallow immunotherapy (SLIT), immunological response, Clinical response, Dose-Response Relationship, specific IgG4

Authors

First Name

Heba

Last Name

Abdelwahab

MiddleName

W.

Affiliation

Chest Medicine Department, Mansoura University, Egypt

Email

wagihheba84@gmail.com

City

-

Orcid

-

First Name

Amina

Last Name

Abd El-Maksoud

MiddleName

-

Affiliation

Chest Medicine Department, Mansoura University, Egypt

Email

aminamahmod@gmail.com

City

-

Orcid

-

First Name

Mohamed

Last Name

A. Elmoneim

MiddleName

-

Affiliation

Chest Medicine Department, Mansoura University, Egypt

Email

dr.m1993@mans.edu.eg

City

-

Orcid

0000-0002-1927-7769

First Name

Mona

Last Name

Shaaban

MiddleName

-

Affiliation

Microbiology & Immunology Department, Faculty of Pharmacy, Mansoura University, Egypt

Email

mona_ibrahem@mans.edu.eg

City

-

Orcid

-

First Name

Mohammed

Last Name

Abu El-Enin

MiddleName

A.

Affiliation

Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Egypt; Department of Pharmacy, Basrah University, College of Science and Technology, Basra 61004, Iraq

Email

mohammed_abu_bakr2000@yahoo.com

City

-

Orcid

-

First Name

Fathalla

Last Name

Belal

MiddleName

-

Affiliation

Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Mansoura University, Egypt

Email

ffbelal@yahoo.com

City

-

Orcid

-

First Name

Abeer

Last Name

Abd El-Aziz

MiddleName

Mohamed

Affiliation

Microbiology & Immunology Department, Faculty of Pharmacy, Mansoura University, Egypt

Email

amafm3@yahoo.com

City

-

Orcid

-

Volume

33

Article Issue

3

Related Issue

47674

Issue Date

2024-07-01

Receive Date

2024-05-18

Publish Date

2024-07-01

Page Start

25

Page End

31

Print ISSN

1110-2179

Online ISSN

2537-0979

Article File

EJMM_Volume 33_Issue 3_Pages 25-31.pdf

PDF . 326.1kB

Link

https://ejmm.journals.ekb.eg/article_357449.html

Detail API

https://ejmm.journals.ekb.eg/service?article_code=357449

Order

357,449

Type

New and original researches in the field of Microbiology.

Type Code

2,038

Publication Type

Journal

Publication Title

Egyptian Journal of Medical Microbiology

Publication Link

https://ejmm.journals.ekb.eg/

MainTitle

Clinical and immunological response to sublingual allergen-specific immunotherapy: cumulative dose-response relationship

Details

Type

Article

Created At

28 Dec 2024